No reliable screening test is available, nor is it likely to be in the foreseeable future. The UK is one of several countries with a gatekeeper healthcare system, where GPs control access to secondary care. Countries with a gatekeeper system have shown to have significantly lower 1-year cancer survival rates. 8 Diagnostic research in this field hasuntil this article -examined kidney cancer along with other urological cancers, but not separately. Furthermore, as bladder cancer is more common, its symptoms will have contributed in a large part to the findings. Moreover, National Institute for Health and Clinical Excellence (NICE) guidelines combine bladder and renal cancers in their recommendations. 9 However, the studies upon which these guidelines were based were largely conducted in secondary care, using patients already selected for investigation, so are typically at a later stage of their disease. There have been no primary care reports examining multiple clinical features of urological cancer, although four primary care studies have examined haematuria, merging kidney, bladder, and sometimes prostate cancers. In one study of patients referred to an open access haematuria clinic, renal cancers were found in six (1.7%) of the 363 in the cohort. 10 A similar Belgian study reported 'other' urological cancers (not bladder) in 39 patients. The positive predictive value (PPV) of visible haematuria was 2.0% for urological cancer. 11 A cohort study using UK electronic records estimated PPVs for haematuria for combined urological cancer of males: 5.5%, (95% confidence interval [CI] = 4.9 to 6.1) and females 2.5% (95% CI = 2.1 to 3.0). 12 No analysis was available for individual cancer sites. In a final study assessing predictors of renal tract cancer, the following symptoms were identified: haematuria, abdominal pain, weight loss, anaemia, and appetite loss (the latter in females only). 13 No PPVs were calculated. Again, the results were not separated by 
results
Cases consulted more frequently than controls in the year before diagnosis: median 16 consultations (interquartile range 10-25) versus 8 (4-15): P<0.001. Fifteen features were independently associated with kidney cancer: visible haematuria, odds ratio 37 (95% confidence interval [CI] = 28 to 49), abdominal pain 2.8 (95% CI = 2.4 to 3.4), microcytosis 2.6 (95% CI = 1.9 to 3.4), raised inflammatory markers 2.4 (95% CI = 2.1 to 2.8), thrombocytosis 2.2 (95% CI = 1.7 to 2.7), low haemoglobin 1.9 (95% CI = 1.6 to 2.2), urinary tract infection 1.8 (95% CI = 1.5 to 2.1), nausea 1.8 (95% CI = 1.4 to 2.3), raised creatinine 1.7 (95% CI = 1.5 to 2.0), leukocytosis 1.5 (95% CI = 1.2 to 1.9), fatigue 1.5 (95% CI = 1.2 to 1.9), constipation 1.4 (95% CI = 1.1 to 1.7), back pain 1.4 (95% CI = 1.2 to 1.7), abnormal liver function 1.3 (95% CI = 1.2 to 1.5), and raised blood sugar 1.2 (95% CI = 1.1 to 1.4). The positive predictive value for visible haematuria in patients aged ≥60 years was 1.0% (95% CI = 0.8 to 1.3).
conclusion
Visible haematuria is the commonest and most powerful single predictor of kidney cancer, and the risk rises when additional symptoms are present. When considered alongside the risk of bladder cancer, the overall risk of urinary tract cancer from haematuria warrants referral. This study aimed to identify and quantify the early clinical features (symptoms, diseases and abnormal investigations) of kidney cancer in primary care, with the intention that this will inform the selection of patients for definitive investigation.
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MEtHod
This was a matched case-control study using patient records in the UK's General Practice Research Database (GPRD), which contains anonymised patient records from nearly 600 general practices across the UK. Data are recorded for all primary care consultations and investigation results. The GPRD applies stringent data quality levels on their practices. 14, 15 Cases and controls Cases had a record of one of 22 GPRD kidney cancer codes (based on Read Codes and linked to ICD-10 classifications; available from authors) between January 2000 and December 2009 inclusive. All were aged ≥40 years with a minimum of 1 year of data before diagnosis. All cancer sites were studied for patients aged ≥40 years as cancers in the under 40s are rare and often atypical. Up to five controls per case were matched to cases by sex, general practice, and age (within 1 year). There is no 'standard' case-control ratio for studies like this, and this study restricted to five by resources, still provided ample power (see below). The first cancer code was taken to be the date of diagnosis, or index date. 14, 15 The controls' index dates matched that of their case. Exclusion criteria were: metastatic cancer to the kidney from a non-kidney primary, diagnosis before 2000, or no consultations in the year before diagnosis. In preparing the dataset the GPRD inadvertently added a bladder cancer code to the dataset. These cases were identified and removed.
Selection of investigations and symptom variables
A list of features potentially associated with kidney cancer was generated from three sources: a traditional literature review using PubMed and EBSCO, patient reported symptoms and clinical knowledge. Selfreported features were taken from several online kidney cancer support organisations and chat rooms and identified through internet searches using search terms like 'kidney cancer', 'kidney cancer symptoms', and 'early signs/indications/symptoms kidney cancer'. Visible and non-visible haematuria were studied separately. The single word 'haematuria' was assumed to be visible haematuria, with only descriptions using the term 'microscopic' or 'trace' assigned to non-visible haematuria. Over 1800 GPRD codes were compiled for the putative features of kidney cancer from the GPRD master list of over 100 000 codes. Occurrences of these features were identified in the year before the index date. Repeated consultations for the same complaint were also identified. Additionally, records of fractures were compiled to identify any recording bias (assuming that the fracture rate would be approximately equal between cases and controls). 14, 15 Any feature reported in fewer than 5% of cases or controls was excluded. Abnormal investigation results were defined as the patient having a test value falling outside their local laboratory's normal range.
Patients with a normal laboratory result were grouped with those who had not been tested. The raised inflammatory markers variable was a composite of any of abnormal erythrocyte sedimentation rate, plasma viscosity, or C-reactive protein; similarly abnormal liver function tests reflected a raised value of any of the hepatic enzymes reported by each laboratory.
Analysis and statistical methods
Analysis followed the protocol used in previous studies. [14] [15] [16] [17] The main method was conditional logistic regression, performed in three stages. First, univariable analysis was conducted on the putative features. These were retained if they had a P-value of ≤0.1, and were grouped for the first multivariable
How this fits in
The clinical features of kidney cancer have not been studied separately in primary care. The study found seven symptoms to be associated with the cancer. All the positive predictive values for these symptoms were very small, apart from haematuria. However, only 18% of patients with kidney cancer had haematuria recorded in their records, so a policy of investigation based solely on that symptom will miss most cancers.
analysis, with retention requiring a P-value ≤0.05. A final multivariable model was compiled from the surviving features of the previous stages. This used a P-value threshold of 0.01. All excluded variables were checked against the final model. Clinically plausible interaction terms were added to the final model and retained if their P-value was also ≤0.01.
Positive predictive values (PPVs) were produced for all features shown to be independently associated with kidney cancer. This was repeated for pairs of symptoms and for second attendances with the same symptom. Bayes' theorem was used to calculate the PPVs (prior odds x likelihood ratio = posterior odds). The prior odds used were the age-specific national incidence of kidney cancer for 2008, expressed as odds. To enable the calculation of PPVs for the consulting population, the proportion of the control population who had not consulted in the year before diagnosis was estimated: 1483 (9.5%) of 15 574 eligible controls had not consulted. PPVs were therefore divided by 0.905 to give the figure for the consulting population.
Power calculations were used rather than sample size calculations 3000 cases and 15 000 controls (the estimates initially provided by the GPRD) provided >98% power (5% two-sided alpha) to detect a change in a rare variable from 1% in cases and 2% of controls. For a commoner variable, the study had >97% power to detect a change in prevalence of 20% in cases to 17% in controls. Data analysis was conducted using Stata software (version 11).
rESultS
The GPRD provided 18 890 patients (3183 cases; 15 707 controls). Application of the exclusion criteria is shown in Figure 1 , leading to a final number of 17 240 (3149 cases; 14 091 controls).
Patient demographic and consultation information is given in Table 1 . Cases consulted significantly more frequently than controls in the year before diagnosis (P ≤0.001; ranksum test).
Clinical features
Twenty-four symptoms and twenty-two abnormal test results were considered initially. Ten symptom and eleven abnormal test variables were present in at least 5% of cases. Just over 1% of cases in this study had a record of non-visible haematuria. Features associated with kidney cancer in univariable and multivariable analysis are shown in Table 2 Table 2 recorded. The proportion of patients with a fracture did not differ between cases and controls (P<0.094).
Positive predictive values Figure 2 shows the PPVs for individual, combined, and repeat features, for patients aged ≥60 years. The top line represents risk for each single feature; below is the risk for combined and repeated features. The greater the number and darkness of the shading shown, the higher the associated risk was.
The likelihood ratios were similar between patients aged 40-59 and ≥60 years. The resulting PPVs were approximately twice as high in the over 60s group. The one exception was visible haematuria, which showed a higher association to kidney cancer in the under 60s group (40-59 likelihood ratio [LR]: 55.6; ≥60 LR: 22.1) The PPV of visible haematuria in the 40-59 years age group was 0.7% (95% CI = 0.4 to 1.3).
dIScuSSIon Summary This study is the first to identify multiple clinical features of kidney cancer in primary care, and quantify them. Seven symptoms, one disease and eight abnormal investigation results were associated with the cancer. The highest single risk was for visible haematuria, being 1.0% for patients aged ≥60 years. Risk increased slightly for repeat symptoms, and when combined with abnormal investigations or abdominal pain. The remaining features were associated with relatively low risk.
Strengths and limitations
The main strengths of this study are its large size, its primary care setting and its sole focus on kidney cancer. The use of GPRD data allowed the study to access thousands of cases from UK general practices. The GPRD is the UK's largest computerised patient record database with an established reputation for data quality and diagnostic validity. 18, 19 Using it ensured patient representativeness across the UK, good power and generalisable results. The large size also enabled sub-analyses by age and sex. Additionally, the start of this study coincides with the period of time when the automatic transmission of laboratory data began. As a consequence, recording error was largely eliminated. Apart from size, another major strength of this study is its setting. The use of primary care data is vital if results are to feed back into future referral selection processes. This is the main clinical problem: deciding who warrants referral, especially in the patient without alarm symptoms. It was particularly useful, therefore, to analyse all clinical features, rather than just haematuria. This allowed for new features to be identified. Additionally, the use of online support group websites allowed us to investigate patient reported symptoms absent from the scientific literature so far. Therefore, it is unlikely that any relevant feature was omitted from this study's list. The nature of this study meant that it was reliant on the accuracy of GP data recording. The GPRD contains many codes, some of which overlap. There will have been variation in GP selection of codes for recording of symptoms, although there is usually a dominant code used by most GPs for that symptom. There will also be some under-recording of symptoms. This is only a problem if present particularly in cases or controls. This was not seen for fractures. If under-recording is approximately equal in cases and controls, the likelihood ratios and PPVs will still be correct. It is possible that pertinent features may have been recorded in the 'free text' section which is the area where GPs can amplify their clinical record without having to use presupplied codes. The GPRD does not release the free-text routinely; for fear that it may lead to de-anonymisation. Nonetheless, a recent study on free-text indicated a high concordance between free-text data and diagnostic coding. 20 The case-control design of this study meant that prior odds could not be calculated from within the study. Instead, the prior odds of cancer from registry data were estimated. The size of the national registries will have provided a more accurate estimate than any cohort study could give.
Comparison with existing literature Almost 30% of renal cancer patients consult their GP three or more times before diagnosis, a marker that has been used as a proxy for delays in diagnosis. 21, 22 The current study fits with this finding, in that cases consulted twice as often as controls. Higher consultations may not represent delays. Indeed they could, in part at least, represent initial investigation for possible urine infection, followed by review. Such clinical practice is good medicine, although there is a fine dividing line between appropriate in-house testing and creating delays. However, existing research has shown that mortality rates worsen in countries where access to specialists is guarded by primary care physicians. 8 Previous primary care research has never studied kidney cancer alone, merging it with bladder and sometimes prostate, ureteric or urethral cancers. The main reported symptom for these cancers is haematuria. The PPV of 1.0%, with narrow confidence intervals, was lower than previous reports, although most of these had small sample sizes, and wide confidence intervals. 11 The closest comparator also used the GPRD, and found PPVs approximately four to five times higher than this study. 12 This can easily be explained by the Jones study also merging bladder and kidney cancer (plus urethra, although it is very rare).
12
A study of bladder cancer alone yielded a PPV for haematuria of 2.6%, which when added to the 1.0% for kidney cancer gives very similar figures to the Jones study.
14 A final primary care study highlighted the importance of clinical features other than haematuria in urological cancers. 13 Symptoms identified for both sexes were: haematuria, abdominal pain, weight loss and anaemia, although combinations of symptoms were not reported. An increased risk when combined with certain abnormal investigations was also found: raised inflammatory markers, thrombocytosis, or microcytosis. Thrombocytosis in primary care cancer diagnosis may be important. An association between thrombocytosis and kidney, pancreatic, and lung cancers was also found.
15,23
Implications for practice There has been a progressive shift towards primary care investigation of possible cancer. Chest X-ray and colonoscopy, for lung and colorectal cancers, have been available for many years without specialist input. Ca125 and transvaginal ultrasound are now available for possible ovarian cancer, and open-access MRI brain was launched in 2012. 24 Abdominal ultrasound is widely available, and this is the main initial investigation for possible kidney cancers. It was hoped to identify symptom complexes other than haematuria, which could have allowed GPs to order an ultrasound. Instead, the results of this study are dominated by haematuria. An ultrasound alone would be insufficient to rule out cancer, as it is not sufficiently accurate in bladder cancer diagnosis. Thus for investigation of haematuria, the twin approach of ultrasound and cystoscopy is still appropriate.
Visible haematuria is the highest individual risk factor for developing kidney cancer. If kidney cancer were the only cancer of interest, then it is questionable if the PPV would warrant testing of all patients with haematuria. However, when the possibility of bladder cancer is added, haematuria per se warrants testing. There are subtle differences between kidney and bladder cancer symptoms.
14 Negative results on both tests will be required to rule out cancer with confidence. The bladder and kidney findings will be merged, and the results fed into the current revision of the NICE guidelines.
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